Management of bone loss after organ transplantation.
Organ transplant recipients experience rapid bone loss and high fracture rates, particularly during the early post-transplant period. Early rapid bone loss occurs in the setting of uncoupled bone turnover with increased bone resorption and decreased bone formation. Because there are no clinical factors that reliably predict post-transplant bone loss and fractures in the individual patient, all transplant recipients should be considered candidates for early preventive therapy for osteoporosis. Long-term transplant recipients with densitometric osteoporosis and/or fractures should also receive treatment. Although active metabolites of vitamin D and bisphosphonates have both shown efficacy, data from clinical trials suggest that bisphosphonates are the safest and most consistently effective agents for the prevention and treatment of post-transplantation osteoporosis in adults. Kidney transplant recipients represent a special population, and more research is needed to delineate the risks and benefits of treating bone disease in these patients.
Cohen
Adi
A
Department of Medicine, Duke University, Durham, North Carolina, USA.
Sambrook
Philip
P
Shane
Elizabeth
E
D015519:Bone Density / Q000187:drug effects; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism; D002986:Clinical Trials as Topic; D003720:Densitometry; D004164:Diphosphonates / Q000494:pharmacology; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods; D016377:Organ Transplantation / Q000009:adverse effects* / Q000379:methods*; D010024:Osteoporosis / Q000517:prevention & control*; D013997:Time Factors; D014807:Vitamin D / Q000494:pharmacology
D004164:Diphosphonates; D014807:Vitamin D